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Recruitment of Pontin/Reptin by E2f1 amplifies E2f
transcriptional response during cancer progression
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Changes in gene expression during tumorigenesis are often considered the consequence of
de novo mutations occurring in the tumour. An alternative possibility is that the transcriptional
response of oncogenic transcription factors evolves during tumorigenesis. Here we show that
aberrant E2f activity, following inactivation of the Rb gene family in a mouse model of liver
cancer, initially activates a robust gene expression programme associated with the cell cycle.
Slowly accumulating E2f1 progressively recruits a Pontin/Reptin complex to open the
chromatin conformation at E2f target genes and amplifies the E2f transcriptional response.
This mechanism enhances the E2f-mediated transactivation of cell cycle genes and initiates
the activation of low binding affinity E2f target genes that regulate non-cell-cycle functions,
such as the Warburg effect. These data indicate that both the physiological and the oncogenic
activities of E2f result in distinct transcriptional responses, which could be exploited to target
E2f oncogenic activity for therapy.
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T
he E2f family of transcription factors is composed of
activator (E2f1-3a) and repressor (E2f3b, 4–8) factors
and is predominantly regulated by the Rb family of
proteins (Rb, p107 and p130)1–4. Activator E2f1-3 display high
conservation of their DNA-binding domains, and previous
studies indicate that they mostly share overlapping target genes.
In contrast, other domains of E2f1-3 are poorly conserved
among the family, suggesting that activator E2fs could interact
with distinct co-factors and thereby modulate their activity in
a context-dependent manner. However, the identity of these
co-factors as well as the consequences of their recruitment in a
variety of physio-pathological contexts is poorly understood5.
Under physiological conditions, Rb proteins maintain cellular
quiescence by binding and repressing the transcriptional activity
of E2f1-3. Mitogenic stimuli-induced stabilization of Cyclin/CDK
complexes and the subsequent phosphorylation of Rb proteins
disrupt the Rb/E2f physical interaction, thereby derepressing E2f
factors and promoting the transactivation of genes associated
with cell cycle and an exit from quiescence6–8. The role of E2f
factors in the regulation of cell cycle is particularly well
established, but evidence indicates that E2f factors also regulate
non-cell-cycle functions under specific conditions. However, how
and in what contexts E2f factors regulate these mostly unknown
non-cell-cycle functions remains unclear1.
Genetic or epigenetic events leading to inactivation of the Rb
family and unrestricted transcriptional activity of E2f factors
are almost universal in cancer9. Besides sustained proliferation,
the consequence of aberrant activity of E2f1-3 on cancer
initiation and progression remains poorly defined, limiting the
development of effective therapies to specifically target oncogenic
E2f activity. In addition to alterations targeting upstream
components of the Rb pathway, activator E2fs are also
overexpressed in tumours. Of interest to this study, E2f1 is
frequently found overexpressed in several types of cancer,
including lung cancer, melanoma and hepatocellular carcinoma
(HCC)1. Data from previous studies suggest that increased E2f1
expression promotes the progression of these cancers, but the
mechanism is mostly unknown10.
HCC is a devastating disease characterized by common
alterations in the Rb pathway following HBV/HCV (hepatitis
B and C viruses) chronic infection and other genetic events, as well
as overexpression of E2f1 (ref. 11). We have previously determined
that ablation of the Rb gene family in the liver of adult mice
(triple knock out-cTKO mice) triggers the development of HCC
(TKO HCC) that recapitulates many histological and molecular
characteristics of the human disease11. In this study, we have taken
advantage of this model to determine the role of E2f factors and
the mechanisms that modulate their transcriptional response
during cancer progression. Our results show that E2f1 recruits the
Pontin/Reptin complex to open chromatin structure at E2f
target genes and amplify their transactivation by E2f factors
during TKO HCC progression. They introduce the concept that
E2f transcriptional response evolves during cancer progression,
including the activation of target genes that control non-cell-cycle
functions such as the regulation of glucose metabolism, also known
as the Warburg effect.
Results
E2f factors regulate the Warburg effect in liver cancer. To
identify novel functions driven by E2f factors during TKO HCC
development, we performed a computational analysis of the
recently published TKO HCC transcriptome11 and identified a set
of genes (Glut4, Pygb, Gsk3b, Pkm2, Pfkl and Mct1) that displays
increased expression in TKO HCC. We validated this finding by
reverse transcription–quantitative PCR for all six genes and
immunoblotting for Glut4 (an average of 12.64-fold induction
compared with controls) and Gsk3a/b (an average of 8.35- and
2.69-fold induction compared with controls for a and b,
respectively) to confirm that these genes are transactivated in
TKO HCC (Fig. 1a,b). These genes regulate multiple aspects of
glucose metabolism (Fig. 1c) and will be described hereafter as
metabolic target genes. To establish the role of E2f factors in the
regulation of metabolic target genes in TKO HCC, we derived two
cell lines from independent TKO HCC primary tumours
(hereafter TKO HCC cells) to serve as an experimental system.
Repression of E2f transcriptional activity by introduction of a
stabilized form of Rb (Rb-7LP)12 (Supplementary Fig. 1a) led to
decreased expression of metabolic target genes (Fig. 1d),
indicating that E2f factors regulate their expression in TKO
HCC. In contrast, genes regulating the tricarboxylic acid cycle
were largely unaltered in TKO HCC (Supplementary Fig. 1b).
To test the consequence of increased expression of metabolic
target genes on glucose metabolism in TKO HCC, we detected
glycogen by periodic acid–Schiff base staining. We found that
TKO HCC tumour zones are depleted of glycogen in contrast
to neighbouring non-tumour zones, thereby correlating with
increased Gsk3b and Pygb expression (Fig. 1e). Substitution of
glucose with galactose (which bypasses glycolysis and promotes
oxidative phosphorylation13) in the culture media of TKO HCC
cells impaired their proliferation, indicating that glycolysis is critical
for TKO HCC proliferation (Fig. 1f). Finally, Rb-7LP expression in
TKO HCC cells led to decreased glucose and glutamine uptake14 as
well as lactate export (Fig. 1g); in parallel, glucose metabolism
shifted towards oxidative metabolism without an increase of the
mitochondrial biomass (Fig. 1h; Supplementary Fig. 1c). These
data show that E2F factors activate a set of genes that alter
glucose metabolism by promoting glycolysis and lactate export
(a phenomenon known as the Warburg effect) in TKO HCC.
Distinct waves of E2f target genes during cancer progression.
This result is unexpected given that alteration of glucose metabo-
lism upon transient exit from quiescence, which is characterized by
robust E2f transcriptional activity, has not been previously repor-
ted. To determine whether metabolic target genes are activated in
the context of transient cell cycle activity, we analysed their
expression in primary hepatocytes, either quiescent or transiently
progressing through the cell cycle (as identified by the expression
of the CyclinB1-green fluorescent protein (GFP) transgene15),
isolated from the liver of 3.5-week-old mice. Although proliferative
hepatocytes display a robust cell cycle programme activation
compared with their quiescent counterparts, they failed to display
any transactivation of metabolic target genes expression (Fig. 2a
and Supplementary Data 1). To test the activation of metabolic
target genes upon short-term inactivation of Rb family genes, we
isolated primary hepatocytes from control and Rosa26-CreERT2
TKO mice after five consecutive daily injection of Tamoxifen. Cell
cycle genes rapidly displayed significant transactivation (albeit at a
lower level of transactivation than was observed in TKO HCC
(Supplementary Fig. 2a)). In contrast, metabolic target genes were
not transactivated in these conditions, with the exception of Glut4,
which displayed limited transactivation (Fig. 2b). These data
suggest a progressive mode of E2f activity: an initial (‘early’) wave
of cell cycle genes is rapidly activated by E2f factors. Following
prolonged E2f activity, another (‘late’) wave of target genes,
composed of genes with non-cell-cycle functions, such as the
regulation of glucose metabolism, is progressively activated by E2f
factors.
To test this hypothesis and determine the evolution of E2f
transcriptional response during TKO HCC progression, we took
advantage of our previous identification of two distinct stages of
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TKO HCC development: (i) early lesions composed of non-
transformed Sca1þ progenitor cells that progressively evolve into
(ii) late lesions composed of well-differentiated tumour cells11.
We compared array analysis performed at each stage
(Supplementary Fig. 2b and Supplementary Data 2) and found
striking differences in gene expression profiles. Among the 17,306
genes expressed at both stages of TKO HCC progression, only a
limited set of 296 genes (highly enriched for E2f target genes with
cell cycle functions (P-valueo10 86; P-value obtained by T-test);
Supplementary Data 3) is commonly upregulated (Fig. 2c, blue
dots), suggesting that proliferation is the only shared feature
between both stages (Supplementary Fig. 2c,d). We found that the
average general transactivation (defined for each stage as the
average fold transactivation for all genes activated at least 2-fold)
is only amplified 1.25-fold from early to late lesions (an average
fold transactivation of 5.35 in early lesions versus 6.67 in late
lesions). In contrast, the average transactivation of the 296 genes
is amplified 2.88-fold from early to late lesions (an average fold
transactivation of 4.1 in early lesions versus 11.8 in late lesions;
Fig. 2d, t-test). Importantly, this amplification occurs in a linear
manner (Fig. 2e), indicating that its underlying mechanism is
independent of the intensity of the initial transactivation
occurring in early lesions.
Based on these computational analyses, we hypothesized that a
set of E2f-regulated target genes is specifically amplified during
TKO HCC progression. To test this hypothesis, we first
investigated the possibility that amplification of E2f transcrip-
tional response is the consequence of decreased activity of
repressor E2f4-8. We found that E2f4-6 expression is unchanged
while E2f7-8 expression is increased in TKO HCC, as expected
since they are themselves E2f target genes16 (Supplementary
Fig. 2e,f). In addition, we found no variation in the binding
intensity of E2f4 to metabolic target genes in TKO HCC


































































































































































































Figure 1 | Rewiring of glucose metabolism in TKO HCC. (a) Reverse transcription–quantitative PCR (RT–qPCR) analysis in control liver (n¼ 5) and TKO
HCC (n¼ 9) for Glut4, Gsk3b, Pygb, Pfkl, Pkm2 and Mct1. (b) Glut4 and Gsk3a/b expression, as detected by immunoblotting in control livers (n¼4) and
TKO HCC (n¼ 10). Loading was normalized by Ponceau staining. (c) Activation of a set of genes (in red) that collectively regulate multiple aspects of
glucose metabolism in TKO HCC. PEP, Phosphoenolpyruvate. (d) RT–qPCR analysis of Ccna2 (Cyclina2) and metabolic target genes expression in TKO HCC
cells 24 h after transduction with a MigR1-IRES-GFP retrovirus either empty (MigR1, white bars) or expressing Rb-7LP (black bars; n¼ 3). (e) Periodic acid–
Schiff (PAS) staining of TKO HCC shows absence of glycogen in tumour zones, whereas adjacent non-tumour zones display normal presence of glycogen.
Upper panel: low magnification of PAS staining (black arrow indicates a tumor zone). Lower panel: high magnification of PAS staining, counterstained with
haematoxylin staining (black arrow indicates glycogen). (f) Growth curve of TKO HCC cells cultured with media containing either 4.5 g l 1 of glucose or
galactose (n¼ 3). (g,h) Metabolites concentration (g) and ROS production (h) in TKO HCC cells 24, 48 or 72 h after infection with empty (white) or Rb-
7LP (black)-expressing MigR1-IRES-GFP retrovirus (n¼ 3), error bars represent standard deviation. *Po0.05; **Po0.01; ***Po0.001. NS, not significant.
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E2f transcriptional response in TKO HCC does not primarily
originate from decreased activity of repressor E2fs.
E2f1 recruits Pontin and Reptin. Based on these observations, we
next hypothesized that activator E2fs increase E2f transcriptional
response by recruiting a novel epigenetic mechanism during TKO
HCC progression. To test this hypothesis, we utilized two parallel
and complementary approaches. First, we screened for the
enrichment of a series of histone modifications in TKO HCC cells
and in primary TKO HCC at a panel of E2f target genes (com-
posed of the 11 genes detected in Fig. 2b). We found that H3k27ac,
H3k9ac, H3k4me3 (which are commonly associated with active
transcription)17,18 are enriched in the regulatory regions of E2f
target genes in TKO HCC cells. This result is not surprising given
the increased transactivation of E2f target genes described above.
More surprisingly, we also found that H2a.z, a histone variant for
H2a associated with destabilization of chromatin and increased
transcription19,20, is enriched in the regulatory regions of E2f
target genes (Fig. 3a,b and Supplementary Fig. 3a). To determine
the frequency of H2a.z enrichment at E2f target genes in TKO
HCC, we performed chromatin-immunoprecipitation sequencing
(ChIP-Seq) analysis with H2a.z and E2f1 pull-down fractions from
TKO HCC cells, which resulted in the identification of 10,014 and
3,581 unique hits genome-wide, respectively. As expected, the
majority of hits in the E2f1 ChIP-Seq were found within or in close
proximity to intergenic regions (Fig. 3c, Supplementary Fig. 3b and
Supplementary Data 4). In addition, H2a.z and E2f1 hits very
significantly overlapped (Fig. 3d), suggesting that enrichment for
the H2a.z histone variant is a common feature of E2f target genes
in TKO HCC.
In a second parallel approach to identify epigenetic regulators
interacting with activator E2fs in TKO HCC, we performed mass
spectrometry (MS) in the pull-down fraction of E2f1 and E2f3 in
TKO HCC cells (Fig. 3e,f). Using this unbiased strategy, we found
that E2f1 co-precipitated with 114 proteins, including multiple
components of the Mll2/3 and Swi/Snf complexes, whereas E2f3
co-precipitated with 53 proteins. Strikingly, we found that the
only common protein in the interactomes of E2f1 and E2f3 is
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Figure 2 | Amplification of E2f transcriptional response during TKO HCC progression. (a) Relative fold expression of metabolic target genes and a
representative set of cell cycle genes upon transient entry of hepatocytes into cell cycle (cycling hepatocytes) and in TKO HCC, compared with their
respective controls. Fold induction is displayed as log2-based intensity ratios. (b) Reverse transcription–quantitative PCR analysis of five representative cell
cycle genes (Ccna2, Cdk2, Mcm2, Mcm3 and Mcm6) and metabolic target genes in control and Rosa26Cre-ER cTKO liver, 5 days after Tamoxifen treatment-
induced Rb family loss (n¼ 3). (c) Comparison of array analysis performed in early and late lesions: fold induction in TKO versus control Sca1þ cells is
displayed on the x axis, whereas fold induction in TKO HCC versus control liver is displayed on the y axis. Blue dots represent the 296 genes transactivated
in both data sets (at least two-fold induction and P-valueo0.05; P-value obtained by t-test). Other genes are represented by red dots. Blue and Red lines
represent average expression for their respective populations. Fold induction is displayed as log2-based intensity ratios. (d) Average amplification of
transactivation levels from early to late lesions. Left: average amplification for the general group (all genes transactivated at least twofold in either early or
late lesions). Right: 296 common target genes group, as identified by blue dots in c (E2f target genes). The box represents the data included within the 25th
to 75th percentile. The horizontal bar represents the average. P-value obtained by t-test. (e) Amplification of the transcriptional activation for the 296
genes (black dots) from early to late lesions (y axis) is plotted against transactivation level in TKO Sca1þ cells versus CT Sca1þ cells (x axis). The black line
represents the average amplification, whereas the grey zone represents the error margin. The horizontality of the line indicates that the transcriptional
amplification is, on average, similar for all genes without any correlation for their transactivation level in early lesions. Error bars represent standard
deviation *Po0.05; **Po0.01; ***Po0.001.
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HCC (Fig. 3e and Supplementary Data 5). Importantly, we found
that E2f1, but not E2f3, specifically interacts with Pontin and
Reptin (also designated as Ruvbl1 and Ruvbl2; Fig. 3f). Pontin
and Reptin are putative DNA helicases with homology to the
bacterial Ruvb protein. They are involved in multiple cellular
processes such as transcription, DNA repair and chromatin
decondensation. Importantly, Pontin and Reptin form a homo/
heterocomplex of 6 or 12 subunits that is both necessary and
sufficient for H2a/H2a.z exchange in nucleosomes21,22. Finally,
the Pontin/Reptin complex can be either found alone or included
in larger complexes such as Tip60 and Srcap23,24. However, our
MS approach as well as ChIP assay for Tip60 protein in TKO
HCC cells failed to identify a role for these larger complexes in
TKO HCC, suggesting that E2f1 recruits isolated Pontin/Reptin
complexes in TKO HCC (Supplementary Fig. 3c and
Supplementary Data 5). Therefore, the combination of our mini
ChIP-screen and MS approaches suggests that E2f1 recruits a
Pontin/Reptin complex to integrate H2a.z and destabilize
chromatin at E2f target genes, resulting in the amplification of
E2f transcriptional response in TKO HCC.
To confirm that E2f1 interacts with Pontin and Reptin, we
performed immunoprecipitation (IP) and reverse-IP for
endogenous proteins in TKO HCC cells. These assays showed
that E2f1, but not E2f2 or E2f3, interacts with Pontin and Reptin
in TKO HCC (Fig. 4a–d, see Supplementary Fig. 7a,b for the
uncropped autoradiogram of Fig. 4a,c, respectively). To identify
the domain of E2f1 involved in this interaction, we performed
glutathione S-transferase (GST)-fusion pull-down assays and
found that E2f1 recruits Reptin through residues 1–88 of its
N-terminal domain (Fig. 4e–g, see Supplementary Fig. 7c for the
uncropped autoradiogram of Fig. 4g). Using a similar GST
pull-down assay, we could not pull-down Pontin with GST–E2f1.
The E2f1 N-domain is not required for DNA binding and is
poorly conserved within the E2f family25 (despite being very well
conserved between mouse and human), thereby supporting the
specificity of Pontin and Reptin recruitment by E2f1.
To determine the fraction of E2f1 that interacts with Pontin/
Reptin, we performed a gradient assay with nuclear extracts from
TKO HCC cells. The 20 collected fractions were run on a
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Figure 3 | Accumulation of the H2a.z histone variant at E2f target genes in TKO HCC. (a) ChIP assay to detect the enrichment of common epigenetic
marks at the promoter region of the panel of E2f target genes (see Fig. 2b for gene list) in TKO HCC cells, as determined by quantitative PCR (qPCR)
analysis (n¼ 3). Green: marks positively enriched; red: marks negatively enriched. (b) ChIP assay to detect the enrichment for the H3k9ac and the
H3k4me3 marks (left) as well as the H2a.z histone variant (right) at the promoter region of the panel of E2f target genes in TKO HCC (black bar, long term
Rb family loss) and in Rosa26 Cre-ERT2 TKO liver 4 days after Tamoxifen treatment (white bar, acute Rb family loss), as determined by qPCR analysis
(n¼ 3). The relative fold enrichment is compared for both conditions with the fold enrichment observed in control liver and arbitrarily set at 1 for the Acute
Rb family loss condition. (c) ChIP-Seq was performed to identify the genomic sequences bound by E2f1 in TKO HCC. The graph determines the distance of
E2f1 bound regions from the closest gene. (d) Venn diagram showing the overlap between E2f1 and H2a.z-bound genes in TKO HCC. P-value obtained by
hypergeometric test. (e,f) E2f1 and E2f3 were pulled-down from TKO HCC lysates and the pull-down fractions were allowed to migrate on an acrylamide
gel subsequently stained with Coomassie Blue for visualization (represented in f) and processed by mass spectrometry (n¼ 3). The relative abundance of
E2f1 (arbitrarily set at 100%), Dp1 (positive control) and Pontin/Reptin in the E2f1 pull-down fraction is indicated on the right of the display. All these
proteins were isolated from the same band migrating at B50 kDa. (e) Summary of the principal findings of the MS performed with E2f1 and E2f3 in TKO
HCC. The complete results are displayed in Supplementary Data 5. Error bars represent standard deviation *P o0.05; **Po0.01; ***Po0.001.
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H2a.z was detected by immunoblotting. This assay showed that
Pontin and Reptin co-migrate in two distinct patterns (lanes 1 to
5 and 7 to 9; Fig. 4h, see Supplementary Fig. 8 for the uncropped
autoradiograms). Interestingly, E2f1 co-migrated with both
patterns of Pontin/Reptin complex but could not be detected in
the lighter fractions, indirectly suggesting that E2f1 is mostly
found in complex with Pontin and Reptin, rather than alone, in
TKO HCC. Finally, H2a.z could only be detected in the heavier
fractions, again indirectly suggesting that H2a.z is only associated
with the heavier forms of the Pontin/Reptin complex.
To determine whether the recruitment of Pontin/Reptin by
E2f1 also occurs in the context of human disease, we repeated the
pull-down fraction of E2f1 in three different human HCC
(hHCC) cell lines. We found that Reptin was present in the E2f1
pull-down fraction in the three cell lines tested, whereas Pontin
was detected in the E2f1 pull-down fractions in HepG2 and
SNU449 cells, but not in Hep3B cells (Fig. 4i). Using a panel of
human cancer cell lines of different origins (Fig. 4j), we found
that E2f1 co-precipitated with Pontin in several lines, indicating
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Figure 4 | E2f1 recruits the Pontin/Reptin complex in TKO HCC. (a) Immunoprecipitation (IP) for IgG, E2f1 and E2f3 in TKO HCC cells. Endogenous E2f1
and E2f3 were pulled-down and the presence of Reptin was detected in the pulled-down fractions by immunoblotting. (b) IP for HA and Reptin in TKO HCC
cells. Endogenous Reptin was pulled-down and the presence of E2f1, E2f2, E2f3, Pontin and H2a.z was detected in the pulled-down fractions by
immunoblotting. H2a.z could only be detected upon IP/western blot. (c) IP for IgG, E2f1 and E2f3 in TKO HCC cells. Endogenous E2f1 and E2f3 were pulled-
down and the presence of Pontin was detected in the pulled-down fractions by immunoblotting. (d) IP for IgG and Pontin in TKO HCC cells. Endogenous
Pontin was pulled-down and the presence of E2f1 and Reptin was detected in the pulled-down fractions by immunoblotting. (e–g) GST constructs
encompassing domains of human E2f1 were generated (e) and their interaction with endogenous Reptin from TKO HCC cells was determined by
immunoblotting (f). (g) The endogenous IP described in a was repeated and increasing amounts of GST-E2f1-1-121 were added to test its capacity to
displace the E2f1/Reptin interaction. The presence of endogenous Reptin in the E2f1 pulled-down fraction was detected by immunoblotting. The E2f1
antibody used in this experiment (C-20) recognizes the C-terminal domain of E2f1. (h) Nuclear extracts from TKO HCC cells were deposited at the top of a
gradient and allowed to migrate through the gradient by ultracentrifugation. Twenty fractions were collected from the gradient and aliquots were run on a
polyacrylamide gel to detect the migration pattern of Pontin, Reptin, E2f1 and H2a.z by immunoblotting. (i,j) Detection by IP of the interaction between E2f1
and Pontin/Reptin in human cancer cell lines: HepG2, Hep3B and SNU4499 (hHCC), NBLS and Be2c (neuroblastoma), DAOY (medulloblastoma), U2OS
(osteosarcoma), T47D (breast cancer), K562 (chronic myeloid leukemia-CML) and EW8 (Ewing sarcoma). Asterisk marks cell lines where Pontin and/or
Reptin interacts with E2f1. (k) E2f1, Pontin and Reptin expression levels in the different cell lines used in i,j as detected by immunoblotting. Normalization
was assessed by Ponceau staining to ensure equivalent loading. *Po0.05; **Po0.01; ***Po0.001.
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E2f1 is a common, albeit not ubiquitous, phenomenon in cancer.
Detection of Pontin, Reptin and E2f1 in protein extracts of all cell
lines used in Fig. 4i,j failed to show any correlation between the
level of protein expression and the formation of Pontin/Reptin/
E2f1 complex, suggesting that context-dependent events must
occur to bring these proteins together (Fig. 4k).
Pontin/Reptin open the chromatin at E2f target genes. To
determine the consequence of Pontin/Reptin recruitment by E2f1
for E2f transcriptional response in TKO HCC, we silenced Reptin
with two different short interfering RNAs (siRNAs) in TKO HCC
cells. Reptin knock-down (Fig. 5a) led to decreased expression of
both Reptin (63% decrease for Reptin siRNA1 and 61% decrease
for Reptin siRNA1) and Pontin (52% decrease for Reptin siRNA1
and 53% decrease for Reptin siRNA1) proteins (Fig. 5b). This
phenomenon has been described previously26 and indirectly
suggests that Pontin/Reptin are mostly present as heteromeric
complexes in TKO HCC. Importantly, Reptin knock-down
repressed the expression of a panel of E2f target genes
(Fig. 5c and Supplementary Fig. 4a) to B2-fold, which is
similar to the repression observed upon expression of Rb-7LP in
TKO HCC cells (Fig. 1d and Supplementary Fig. 4b) and correlate
with the 2-fold amplification observed from early to late lesions
***
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Figure 5 | Critical role for the chromatin remodelling functions of Reptin in TKO HCC. (a) Intensity of Reptin silencing in TKO HCC cells upon their
transfection with either Scramble, Reptin1 or Reptin2 siRNAs, as determined by quantitative PCR (qPCR; n¼ 3). (b) Expression of Reptin (upper panel), Pontin
(middle panel) and Gapdh (lower panel) in TKO HCC cells transfected with either Scramble, Gapdh or Reptin1 or Reptin2 siRNAs, as detected by
immunoblotting (n¼ 3). (c) Average expression level of the panel of E2f target genes (see Fig. 2b for genes list) upon transfection of TKO HCC cells with
Scramble (white), Reptin1 (grey) and Reptin2 siRNAs (black), as determined by reverse transcription–quantitative PCR analysis (n¼ 3). (d,e) ChIP assay to
detect the enrichment for E2f1, E2f3 (d) and H2a.z (e) at the promoter region of the panel of E2f target genes upon transfection of TKO HCC cells with
either Scramble (white) or Reptin2 (black) siRNAs, as determined by qPCR analysis (n¼ 3). (f) Decreased DNAseI hypersensitivity upon Reptin silencing in
TKO HCC cells. Accessibility of promoter regions from cyclina2, mcm3, mcm6, glut4, gsk3b and pkm2 were assessed by qPCR, with non-promoter regions of
gapdh as an internal control (n¼ 3). (g) Growth curve of TKO HCC cells infected with the MigR1-IRES-GFP retrovirus either empty or expressing the wild-
type (WT) and point mutant forms of human Pontin and Reptin. 50,000 cells were plated in six wells in triplicates and counted every day. This experiment
has been performed three times independently and the panel displays the data from one representative experiment. (h) Representative image of cells
expressing Reptin D299N point mutant. Cells expressing Reptin D299N (as identified by GFPþ expression, arrow) display a cellular crisis-like morphology
and do not form colonies. They are outcompeted in the dish by rare GFP cells that display normal morphology and growth behaviour (colony on the right
side of the picture). Normal morphology was also observed for all GFPþ cells expressing WT Pontin, WT Reptin and point mutant Pontin. Error bars
represent standard deviation *Po0.05; **Po0.01; ***Po0.001.
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(Fig. 2c–e). In addition, Reptin knock-down decreased the
binding of both E2f1 and E2f3 to the regulatory regions of the
panel of E2f target genes (Fig. 5d and Supplementary Fig. 4c),
indicating that Pontin/Reptin recruitment by E2f1 increases the
binding of E2f factors to E2f target genes and amplifies their
transactivation. Reptin knock-down also decreased the presence
of H2a.z, suggesting that Pontin/Reptin recruitment may alter the
conformation of chromatin at the regulatory regions of E2f target
genes in TKO HCC. To test this hypothesis, we performed a
DNAseI hypersensitivity assay in TKO HCC cells upon Reptin
knock-down and found that the partial silencing of Reptin
expression led to decreased accessibility of the regulatory regions
of E2F target genes (Fig. 5f). Overexpression of wild-type Pontin
and Reptin did not alter the proliferative capacity of TKO HCC
cells in vitro. In contrast, expression of a point mutant form of
Reptin (D299N, which ablates the chromatin remodelling
capacity of Reptin)27, but not Pontin, abolished the proliferative
capacity and altered the morphology of TKO HCC cells
(Fig. 5g,h). Finally, partial knock-down of E2f1 led to a modest
reduction of E2f target gene expression but failed to modify the
proliferative capacity of TKO HCC cells, in line with previous
reports (Supplementary Fig. 4d,e). Collectively, these data
indicate that the recruitment of Pontin/Reptin complexes by
E2f1 opens up chromatin conformation at E2f target genes and
amplifies their transcription by E2f factors.
Progressive formation of the E2f1-Pontin/Reptin complex.
Data from Figs 1 and 2 suggest that the amplification of E2f
transcriptional response is a progressive phenomenon in TKO
HCC. To identify the mechanism that underlies the progressive
nature of this phenomenon, we first determined the evolution of
E2f factors expression in TKO HCC. Although E2f2, E2f3 and
E2f4 protein expression levels are mostly unaltered, we found that
E2f1 expression increases in TKO HCC compared with control
livers (Fig. 6a; an average of 2.61-fold induction for E2f1 com-
pared with controls, 1.07- for E2f2, 1.3- for E2f3 and 0.84-fold






















































































































































































Figure 6 | Progressive recruitment of Pontin/Reptin by E2f1 in TKO HCC. (a) E2f1, E2f2, E2f3, E2f4 and Gapdh (normalization) expression levels in
control liver and TKO HCC, as detected by immunoblotting. (b) IP for HA, E2f1 and E2f3 in primary liver extracts from cTKO (d0), Rosa26-CreERT2 TKO 4
days after Tamoxifen treatment (d4) and TKO HCC. Reptin (upper panels) and Pontin (middle panels) were detected in the pull-down fractions at each
time point by immunoblotting. Expression levels of E2f1, E2f3, Reptin and Pontin were detected at the different time points in the corresponding input
fractions by immunoblotting (lower panels). (c) H2a.z, Pontin, Reptin and Actin protein expression in control liver and TKO HCC, as detected by
immunoblotting. Ponceau staining is used for normalization purpose. (d) mRNA expression for Reptin and Pontin in control liver (n¼ 5) and TKO HCC
(n¼9), as detected by qPCR. (e) mRNA expression for H2a.z in control liver (n¼ 5) and TKO HCC (n¼ 9), as detected by qPCR. (f) Binding of E2f1 to the
promoter region of H2a.z (following the identification of an E2f-binding site in the promoter of H2a.z), as shown by ChIP assay in TKO HCC cells (n¼ 3).
(g) Repression of H2a.z expression in two clones of TKO HCC cells (2.1 and 1.1) upon infection with retroviruses either control (MigR1) or expressing the
Rb-7LP protein (n¼ 3). (h) Left: Frequency of E2F1 expression in tissue microarray (TMA) encompassing human HCC cases from stages I–IV. Right:
Representative E2F1 staining of two independent HCC cases classified as stage IV HCC. Error bars represent standard deviation *P o0.05; **P o0.01;
***Po0.001. WB, western blot.
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recruit Pontin and Reptin in TKO HCC but not upon acute Rb
family inactivation, which correlates with the progressive accu-
mulation of E2f1, as well as Pontin and Reptin (Fig. 6b). In
addition to E2f1, we found that Pontin, Reptin and H2a.z also
display higher expression in TKO HCC compared with control
livers (Fig. 6c–e, see Supplementary Fig. 9a for the uncropped
autoradiograms and the Ponceau staining of Fig. 6c; an average of
11.44-fold for H2a.z compared with controls, 3.39-fold for Pontin
and 4.02-fold for Reptin) and our data identified H2a.z as a new
E2f target gene (Fig. 6f,g). To correlate these findings with the
human disease, we performed staining of Tissue Microarray with
anti-E2F1 antibody and found that E2F1 is restricted to the latter
stages of hHCC, indirectly indicating that E2F1-Pontin/Reptin
complex can only be observed in the advanced stages of the
hHCC (Fig. 6h). Together, these data suggest that the progressive
nature of E2f transcriptional response amplification in TKO HCC
results from the combined accumulation of E2f1, Pontin, Reptin
and H2a.z during TKO HCC progression, which recapitulates the
expression of these factors in the hHCC. However, data from
Fig. 4k suggest that the global mechanism of Pontin/Reptin/E2f1
complex formation in cancer is likely more complex.
E2f-binding affinity dictates the kinetic of activation.
Amplification of E2f transcriptional response by Pontin/Reptin
recruitment does not elucidate the mechanism that underlies the
existence of distinct waves of E2f target genes during TKO HCC
progression. ChIP assay with E2f1 and E2f3 upon acute Rb family
deletion in primary cTKO liver (d0, d4) and in TKO HCC
showed an inverse evolution of E2f1- and E2f3-binding intensity
during TKO HCC progression (Fig. 7a,b). The relative ratio of
E2f1 (average of 1.47 ng ml 1) versus E2f3 (average of
2.27 ng ml 1) protein abundance in TKO HCC correlates with
the twofold reduction of E2f3 binding over time and E2f1 accu-
mulation (Fig. 7c,d). Importantly, we found that E2f1 and E2f3
consistently bound with higher affinity to cell cycle target genes
compared with metabolic target genes at any time of TKO HCC
progression (Fig. 7a,b; see Fig. 2b for the list of the 11 target
genes). Based on these data, we hypothesized that the sequence of
the E2f-binding site located in the promoter region of E2f target
genes plays a crucial role in dictating E2f-binding activity and
consequently the kinetic of activation by E2f factors during TKO
HCC progression. Of note, the 50-TTTSSCGC-30 sequence is
considered the canonical binding sequence for E2f, but work from
the Farnham group showed that the 50-SSCGC-30 sequence is
sufficient for E2f1 binding, with a minimal role for neighbouring
sequences located around the E2f-binding site25. Accordingly,
alignment of literature- and ChIP-validated E2f-binding sites for
genes from both early (296 cell cycle genes as identified in Fig. 2c)
and late (metabolic and Notch pathway target genes) waves led to
the establishment of a consensus sequence for both groups.
Although the 50-SSCGC-30 sequence was overall conserved in
both groups, only genes from the early wave display a
50 T(thymine)-stretch adjacent to this minimal binding site
(Fig. 7e,f). To test whether the T-stretch is critical to determine
E2f-binding affinity to target genes, we performed gel shift assay
with biotin-labelled probes containing the early consensus (as
identified in Fig. 7f) and the Pfkl (which does not contain any
thymine residue) sequences. We found that the early consensus
probe bound to E2f1 and E2f3 (lanes 4–8 for supershift (Ss) with
increasing amount of anti-E2f1 and-E2f3 antibodies) with more
intensity than the Pfkl probe (Fig. 7g, compare lanes 1 and 4).
However, the inclusion of a T-stretch in the Pfkl probe increased
E2f binding to a level similar to the early consensus probe
(compare lanes 1–2 and 4). Gel shift performed in a in vitro
context with increasing amount of GST–E2f1 and identical
quantity of Pfkl and Pfkl T-stretch probes showed that E2f1
display higher affinity for the latter probes (Fig. 7h and
Supplementary Fig. 5a, see Supplementary Fig. 9c for the
uncropped autoradiogram). These results show that the
presence of the T-stretch is a unique feature of early E2f target
genes and increases the affinity of E2f for binding to target genes,
suggesting that the sequence of the E2f-binding site present in the
regulatory region of E2f target genes underlies the kinetics of E2f
target genes activation upon sustained E2f activity.
Finally, we analysed the intersection of genes bound by E2f1
(obtained from the ChIP-Seq experiment described in Fig. 3c,d)
and genes transactivated in TKO HCC. Albeit significant
(P-valueo10 8), the overlap was fairly limited, with 260 genes
present at the intersection of both data set (Fig. 7i and
Supplementary Data 6). In contrast, analysis of the genes
transactivated in TKO HCC and the genes bound by haemagglu-
tinin (HA)-tagged exogenous E2f1 in breast cancer cells25
identified 549 genes at the intersection of both data sets
(P-valueo10 55; Fig. 7j), suggesting that ChIP-Seq
experiments performed by pulling-down endogenous proteins
may only detect high-affinity binding target genes and ignore a
significant fraction of target genes bound by E2f1 with low
affinity.
Discussion
Our data have identified an epigenetic mechanism recruited by
E2f1 to amplify E2f transcriptional response during the progres-
sion of a pre-clinical model of HCC. We show that the net
outcome of this mechanism is the enhanced transactivation of cell
cycle genes and the de novo transactivation of novel E2f target
genes that display low-affinity E2f-binding sites in their
regulatory regions, such as genes regulating glucose metabolism
and the Warburg effect (Fig. 8).
In the current model of tumour evolution, a succession of
independent genetic and epigenetic events drives discrete changes
in the transcriptional landscape of the tumour, leading to the
progressive acquisition of new oncogenic features that support
tumour development28,29. Our data introduce an alternative
model (although not mutually exclusive) wherein the E2f
transcriptional response gradually evolves over time following
the amplification of E2f transcriptional activity. These results
suggest that E2f transcriptional response upon transient E2f
activation is limited to high binding affinity target genes that
regulate the progression through cell cycle. In contrast, E2f
transcriptional response upon sustained E2f activity expands to
many additional target genes that harbour low-affinity
E2f-binding sites in their regulatory regions. Here, we have
identified a set of these low-affinity target genes that regulate the
Warburg effect. Therefore, our data establish E2f as a central hub
in the regulation of proliferation and energy metabolism in cancer
cells. Our previous work identified additional E2f target genes
with non-cell-cycle functions in the context of Rb family
deficiency, such as the Notch pathway genes for liver cancer11
and Foxn1 for thymus development30. Still, it is likely that these
target genes only represent a small fraction of low-affinity
E2f-binding genes. This prediction is in agreement with our
ChIP-Seq results and ChIP-Seq results generated by the Farnham
group, which led to the identification of more than 10,000
binding sites (corresponding to 5,789 genes) for E2f1 in breast
cancer cells, the majority of which only harbours the 50-CGCGC-
30 binding site25. However, the fact that E2f factors have low
binding affinity for these target genes suggest that their detection
in genome-wide sequencing approaches may be technically
challenging. This possibility is further supported by the
comparison of our ChIP-Seq analysis, performed with
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Figure 7 | Distinct classes of E2f target genes based on E2f affinity for their promoter regions. (a,b) ChIP assays for E2f1 (a) and E2f3 (b) to detect their
enrichment at the promoter regions of representative cell cycle or metabolic target genes (see Fig. 2b for gene lists) at different time points upon Rb family
loss, as determined by quantitative PCR (n¼ 3). (c,d) Quantification of E2f1 and E2f3 proteins expressed in TKO HCC. Protein extracts from TKO HCC
tumours were run on a polyacrylamide gel in parallel with increasing amount of recombinant E2f1 (c, upper panel) and E2f3 (c, lower panel) proteins.
Expression of E2f1 and E2f3 was quantified using the standard curve established with recombinant proteins. The average expression is displayed in d for
better comparison. The box represents the data included within the 25th to 75th percentile. The horizontal bar represents the average. (e) Alignment of
ChIP validated E2f-binding sites from cell cycle and metabolic target genes. Canonical E2f-binding site is found within the red rectangle and thymine
residues are in bold. (f) Identification of consensus binding sites for early and late sets of E2f target genes. The consensus site for the early genes was
obtained by collapsing the sequences of the E2f-binding sites identified in the set of 296 genes (see Fig. 2c for details). The consensus site for the late
genes was obtained by collapsing the sequences of the E2f-binding sites located in the promoter region of the metabolic target genes and the Notch
signalling genes11. The red box identifies the high-affinity binding site, which includes the T-stretch. The blue box identifies the minimal sequence,
50-SSCGC-30, required for low-affinity binding. (g) Gel shift assay to determine E2f1- and E2f3-binding affinity to probes containing either the early
consensus sequence, the Pfkl sequence and a T-stretch mutated Pfkl sequence. Complexes were supershifted with increasing amount of E2f1 or E2f3
antibodies. Ss: supershift. Free probe is displayed at the bottom of the panel. (h) Gel shift assay with increasing amount of recombinant GST–E2f1 incubated
with constant amount of the Pfkl and Pfkl T-stretch probes. (i,j) Intersection of genes transactivated in TKO HCC with gene sets identified in the E2f1
ChIP-Seq experiment performed in TKO HCC (i) and in MCF7 cells stably expressing HA-E2f1 by the Farnham group (j). P-value obtained by
hypergeometric test. Error bars represent standard deviation *P o0.05; **P o0.01; ***Po0.001.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10028
10 NATURE COMMUNICATIONS | 6:10028 | DOI: 10.1038/ncomms10028 | www.nature.com/naturecommunications
endogenous E2f1 protein, and ChIP-Seq performed previously
with overexpressed tagged E2f1 (Fig. 7i,j). Improvement of ChIP
techniques is needed to identify low-affinity E2f target genes but
it is likely that their functions expand well beyond the regulation
of cell cycle activity. Finally, these ChIP-Seq data identify many
genes bound, but not transactivated, by E2f1 in TKO HCC
(Fig. 7i, 3,321 hits), which suggests that a permissive chromatin
environment or the presence of additional co-factors is necessary
for the efficient transactivation of genes bound by E2f factors.
Previous reports have shown that the recruitment of Pontin/
Reptin complex increases the transcriptional response of Myc31
and Oct4 (ref. 32), suggesting that this complex modulates
transcriptional activity in a number of different cellular and
molecular contexts. Mechanistically, Pontin and Reptin are
related to a family of AAAþ ATPase helicases and they display
multiple functions such as the regulation of transcription, DNA
repair and chromatin remodelling protein24. Results shown in
Fig. 5 indicate that the recruitment of Pontin/Reptin by E2f1
opens chromatin at E2f target genes (as evidenced by the
decreased presence of H2a.z and the reduced DNAseI sensitivity
upon Reptin silencing in TKO HCC cells), which impacts the
capacity of E2f factors to bind to their target genes. Indeed, our
data in Fig. 7a–d show that the regulatory regions of E2f target
genes are occupied by several E2f factors and the consequence of
Pontin/Reptin activity on chromatin conformation may explain
why E2f3 binding is also impacted by Reptin knock-down,
although it does not physically interact. However, this model
requires further experimental validation and it is likely that the
mechanism of transcriptional amplification by Pontin/Reptin is
more complex. Last, our data indicate that only the chromatin
remodelling activity of Reptin is required in the TKO HCC
setting. In contrast, Pontin interacts with Reptin and E2f1 but its
chromatin remodelling activity is not required in TKO HCC
(Fig. 5g). As shown in Fig. 5b and demonstrated by others, Reptin
and Pontin depend on each other for their stability. In the context
of TKO HCC, we therefore hypothesize that the role of Pontin in
the E2f1-Pontin/Reptin association may be limited to scaffolding
functions that stabilize Reptin expression and enable Reptin-
mediated chromatin remodelling activity. However, more
mechanistic studies will be required to understand this
phenomenon, which is likely to be cell-type dependent.
Our unbiased MS approach has led to the identification of
many interacting partners for E2f1 and E2f3. Surprisingly, the
only common interactor for both E2f proteins is Dp1, which is
required for their transcriptional activity. The DNA-binding
domain is highly conserved among E2f members1 and genetic
experiments and transcriptional profiling have indicated strongly
overlapping list of target genes for activator E2fs1. Our data
suggest that the specificity of activator E2f functions may not
reside in the identity of bound target genes but rather in the
capacity of the different activator E2fs to recruit co-factors to
modulate the transactivation of otherwise common target genes
in a context-dependent manner.
Non-DNA-binding regions are poorly conserved among
E2f factors and it is therefore not surprising that E2f1 recruits
Pontin/Reptin through its N-terminal domain. The N-domain of
E2f1, which is highly conserved across species, is also necessary to
recruit know interactors of E2f1 such as CyclinA2. The fact that
E2f1 appears to recruit so many interactors, including several
chromatin regulators such as Pontin/Reptin, Mll2 and Swi/Snf
complex, raises multiple questions regarding these interactions:
do they occur simultaneously, sequentially or in a competitive
manner? And are post-translational modifications required for
the recruitment of these interactors? Although work from others
has already shed light on the recruitment of co-factors by E2f1,
our data indicate that this process is likely very complex and
more work is need to fully understand its mechanism and
transcriptional consequence.
The evolution of E2f transcriptional response in TKO HCC
correlates with the evolution of the transcriptional landscape
during hHCC progression, including the expression of key
markers of hHCC progression such as CD34 and Igfals
(Supplementary Fig. 6a,b)33. Increased expression of E2f1 is a
common feature of several types of cancers such as melanoma
and HCC10. Although the mechanism of action is poorly
understood, it appears that E2f1 activity plays a critical role in
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Figure 8 | Progressive amplification of E2f response during cancer progression. Model for the evolution of E2f transcriptional output in TKO HCC. Upon
Rb family loss, TKO liver cells enter cell cycle activity. Early lesions composed of proliferative Sca1þ progenitor-like cells can be detected after 2–5 weeks
and gradually turn into late lesions macroscopically visible by B4 months of age (TKO HCC). In quiescent cells, Rb family represses the transcriptional
activity of E2f and the dimerization partner Dp1. Upon acute Rb family loss, E2f2 and E2f3 activate the transcription of cell cycle genes and E2f1. During TKO
HCC progression, E2f1 gradually binds to the promoter region of E2f target genes and recruits Pontin and Reptin to incorporate H2a.z and amplify E2f
transcriptional response. This mechanism leads to increased transactivation of cell cycle target genes (early genes displaying high-affinity E2f-binding sites
in their promoter regions) and activation of non-cell-cycle target genes (late genes displaying low-affinity E2f-binding sites in their promoter regions),
including genes that regulate the Warburg effect, Notch signalling and most likely other oncogenic features.
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the progression of these cancers at an established stage. In
parallel, overexpression of Pontin and Reptin is also a frequent
feature of many types of cancer, including HCC22,34. Work by the
Rosenbaum group has shown that repression of Pontin/Reptin
expression or chemical inhibition of their ATPase activity is
sufficient to inhibit the proliferation of HCC cells in vitro and in
xenograft transplants27,35,36. Although Pontin and Reptin have
other binding partners that are relevant for cancer progression
such as b-catenin and Myc31,37, our results, combined with the
frequent aberrant E2f activity in cancer, suggest that their
recruitment by E2f1 may be a common mechanism to drive
cancer progression. Impairing the enzymatic activity of Pontin/
Reptin in vivo is likely to induce strong adverse effects (supported
by the early lethality of Pontin-deficient mice). However,
impairing the recruitment of Pontin/Reptin by E2f1 may prove
a valuable alternative strategy. In the future, it will be important
to determine the mechanism of Pontin/Reptin recruitment by
E2f1 in order to establish the therapeutic relevance of targeting
this interaction.
Methods
Mice. Rb-family cTKO mice38 were maintained on a mixed 129Sv/J;C57/BL6
background. For intrasplenic injections, mice (male and female, between two
and four months of age) were anaesthetized and surgically opened on the upper left
flank and adenovirus was injected into the spleen. In Rosa26-CreERT2 TKO mice,
Cre expression was induced by intraperitoneal injection of 1 mg of Tamoxifen
(Sigma) in corn oil for 5 consecutive days. Mice were housed in the CHOP
barrier facility. All experiments with mice were approved by the Children’s
Hospital of Philadelphia Institutional Animal Care and Use Committee (CHOP
IACUC) (protocol #969).
Cell culture and infections. TKO HCC cells were cultured in DMEM with sodium
pyruvate, L-glutamine and phenol red (Mediatech), supplemented with 10% fetal
calf serum and 1% penicillin–streptomycin–glutamine (Invitrogen). Rb-family
TKO1.1 and 1.2 cell lines were derived from independent liver tumours in
Rb-family TKO mice11. Experiments have been performed in both cell lines with
similar results and they are collectively referred to as TKO HCC cells. A super-
repressor form of Rb containing the Rb large-pocket domain (Rb-7LP39, a generous
gift from Eric Knudsen) was inserted into the XhoI site of MigR1-IRES-GFP
retroviral (generously provided by Warren Pear, University of Pennsylvania).
cDNA of human Pontin and Reptin, either wild-type or their point mutant
versions (D302N and D299N, respectively; a kind gift of Jean Rosenbaum,
Bordeaux, France) were also subcloned in the MigR1-IRES-GFP retroviral vector.
An empty MigR1-IRES-GFP vector was used as a mock infection control.
Retroviral vectors were transfected into PlatE cells by calcium phosphate
transfection as previously described40. TKO cells were infected with media from
transfected PlatE cells and collected after 24, 48 or 72 h. Three hairpins
corresponding to Scramble or targeting E2f1 mRNA were cloned in pSicoR-GFP.
Lentiviral supernatant was produced in 293T cells cultured in DMEM. Silencer
Select siRNAs (Gapdh, Scramble, Reptin 1&2 siRNA, Invitrogen) were transfected
into TKO HCC cells with Lipofectamine 2000 (Invitrogen). Block-iT FITC-tagged
oligos (Invitrogen) were used as transfection controls. Cell media were changed 4 h
following infection. Cells were harvested after 48 or 72 h following transfection for
ChIP analysis, RNA or protein extraction. The panel of human cancer cell lines was
grown in DMEM or RPMI supplemented with 10% FBS and 1% penicillin–
streptomycin–glutamine.
Metabolic assessment. For growth assays, 50 105 cells were seeded and grown
in DMEM containing glucose (4.5 g l 1) or glucose-free DMEM supplemented
with galactose (4.5 g l 1). Cells were counted manually on a haematocytometer for
5 days. For metabolite concentration assays, TKO HCC cells were infected with
either empty or Rb7LP-MigR1-IRES-GFP. Cells were collected 24 h after infection
and sorted for GFP expression on a MoFloXDP sorter (Beckman-Coulter). The
GFPþ fraction was replated and cultured for 48 or 72 h. Media were collected from
cell cultures and assayed using an YSI 7100 reader (equipment generously provided
by Kathryn Wellen, University of Pennsylvania). Reactive oxygen species (ROS)
production was assayed using MitoSOX Red Mitochondrial Superoxide Indicator
(Invitrogen, M36008). TKO cells infected with Rb7LP-MigR1 or empty MigR1
were harvested after 48 or 72 h and stained with Mitosox according to the man-
ufacturer’s specifications. Cells were analysed on a C6 Accuri analyzer (BD). For
paraffin sections, organs were fixed in 4% formaldehyde overnight at room tem-
perature and transferred to 70% ethanol before processing and embedding. Peri-
odic acid–Schiff base staining was performed according to the manufacturer’s
specifications (Sigma, 395B-1KT). Slides were counter stained with haematoxylin
and eosin where indicated. Slides were imaged on an Olympus IX81 inverted
microscope.
Quantitative PCR. Total RNA was extracted from cell lines and primary tissue
directly into either Trizol or Trizol LS for FACS-sorted cells (Life Technologies)
and purified with the RNeasy Mini kit (Qiagen). Complimentary DNA was
generated with the Protoscript First Strand cDNA Synthesis kit (New England
Biolabs). Quantitative PCR was performed in duplicate with SYBR Green PCR
Master Mix (Life Technologies) on the Viia7 Real-Time qPCR system (Life
Technologies). Data were normalized using actin or gapdh as a reference gene.
Primer sequences are available in Supplementary Table 1.
ChIP assay and ChIP-Seq. Cell lines were collected into 0.5% SDS lysis buffer at a
density of 50 106 cells per ml and crosslinked in 2% formaldehyde for 10 min.
Lysates were sonicated on a BioLogics Model 3000 Ultrasonic Homogenizer for
30 s at 40% power on ice to produce chromatin fragments of B400–700 bp. For
ChIP experiments using primary liver tissue, livers were perfused in situ via the
inferior vena cava with 30 ml of 2% formaldehyde over 5 min. Livers were removed,
weighed, minced and homogenized in a Potter-Elvehjem hand-powered homo-
genizer. Homogenate was treated an additional 10 min in 2% formaldehyde to
crosslink. Primary cells were washed, filtered through a 70-mm filter, lysed in buffer
containing 1% SDS at a density of 0.1 g tissue per ml and sonicated for eight cycles
of 30 s at 40% power followed by 30 s of rest. Cell lysates were pre-cleared with
Protein A-conjugated Sepharose beads (Life Technologies) for 1 h at 4 C. Pre-
cleared lysates were then incubated overnight with 10 mg antibody at 4 C. Anti-
bodies used for IP are as follows: E2F1 (Santa Cruz, SC-193X), E2F3 (Santa Cruz,
SC-878X), H2a.z (Abcam, ab4174), H3k27ac (Abcam, AB4729), H3k27me3
(Millipore, 07-449), H3k9ac (Abcam, AB10812), H3k9me3 (Abcam, AB8898),
H3k4me3 (Abcam, AB8580), H3k4me1 (Abcam, AB8895), H4k20me3 (Abcam,
AB9053), H3r17me2 (Abcam, AB8284), H3s10ph (Abcam, AB5176). Antibodies
were pulled down with Protein A beads for 1 h at 4 C. Beads were collected,
washed and eluted. Eluates were treated with RNase and Proteinase K for 30 min at
37 C then treated with NaCl and incubated overnight at 65 C to reverse cross-
links. DNA was purified from eluates using phenol-chloroform isoamyl alcohol
extraction. DNA fragments were analysed by quantitative PCR with SYBR Green
reagents. Samples were normalized to input DNA. We could not perform ChIP
assays for E2f2, because of the lack of a specific antibody available for this purpose.
To perform ChIP-Seq for H2a.z and E2f1, a similar procedure was achieved to
isolate the genomic fraction. Genomic DNA samples (input and pull-downs) was
quantified by bioanalyser and further processed by the genomic core facility at the
University of Pennsylvania. Raw data are available in Supplementary Data 7 and 8.
We used a list of genes previously identified as E2F1-bound genes in MCF7 cells by
the Farnham group. To perform this experiment, this group generated stable
transfectant of MCF7 cells expressing HA-E2F1-ER cDNA, where E2F1 is activated
upon Tamoxifen treatment and E2F1 was pulled-down for ChIP-Seq using an anti-
HA antibody.
GST fusion pull-down assay. E2F1 GST-fusion proteins were produced in BL21
strain. Bacteria were grown to an optical density (A595) of 0.5, and then induced with
0.5 mM isopropyl-1-thio-b-D-galactopyranoside for 2 h before harvesting. Bacterial
pellets were lysed in 30 ml of NENT buffer (250 mM NaCl, 1 mM EDTA, 20 mM
Tris, pH 8, 1.5% Nonidet P-40) and sonicated three times for 15 s at 4 C. Debris was
removed via centrifugation. GST fusion proteins were purified by incubating the
saved supernatant with 40ml GST-sepharose beads for 2 h at 4 C. Beads were
washed two times in 1 ml of NENTM buffer (NENT, 0.5% milk) and once with TWB
buffer (20 mM HEPES, pH 7.9, 60 mM NaCl, 2 mM dithiothreitol, 6 mM MgCl2,
8.2% glycerin, 0.1 mM EDTA). Fusion proteins were run on a 4–12% polyacrylamide
gel then visualized for normalization with Coomassie blue. GST pull-down assay was
performed by incubating 1 ml TKO cell lysates with an aliquot of GST bead-bound
fusion protein in 200ml of TWB buffer for 1 h. Beads were washed five times with
1 ml of NENTM buffer, loaded with 4 LDS Sample Buffer w/.05% b-mercap-
toethanol, then run on a 4–12% SDS–polyacrylamide gel for autoradiography.
Lysates for MS and IP. Cell lines were harvested in HEPES Lysis Buffer (200 mM
K-HEPES, pH 7.4, 1.1 M KOAc, 20 mM MgCl2, 1% Tween-20, 10mM ZnCl2,
10 mM CaCl2, 500 mM NaCl, 2% Triton X-100, Protease Inhibitor Cocktail) at a
density of 40 106 cells per ml and were pre-cleared for nonspecific binding with
Protein A-conjugated Sepharose beads for 1 h at 4 C. Relevant antibodies were
incubated with lysates for 1 h at 4 C. 40ml of Protein A-conjugated sepharose
beads were added to lysates and incubated for an additional 1 h at 4 C. Beads were
washed three times in lysis buffer then unconjugated with 20 ml of 4 LDS Sample
Buffer w/.05% b-mercaptoethanol. Antibodies used were HA (Santa Cruz,
SC-7392), E2F1 (Santa Cruz, SC-193), E2F3 (Santa Cruz, SC-878), Reptin (Sigma,
2E9-5) and Pontin 52 (Santa Cruz, SC-81360).
Mass spectrometry. Each sample was run on an SDS–polyacrylamide gel elec-
trophoresis, cut into eight even slices, further cut into 1 mm cubes reduced, alky-
lated and digested with trypsin. Tryptic digests were analysed by LC-MS/MS on a
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hybrid LTQ Orbitrap Elite mass spectrometer. All MS/MS samples were analysed
using Sequest (Thermo Fisher Scientific), against a Uniprot Mus musculus com-
plete proteome database (20130819, 51891 entries) appended with common con-
taminants. Scaffold (version Scaffold_4.3.4, Proteome Software Inc.) was used to
validate MS/MS-based peptide and protein identifications.
Protein biochemistry. To quantify the abundance of E2F1 and E2F3 proteins, we
used the corresponding recombinant proteins (Origene) and loaded increasing
amounts on a polyacrylamide gel, in parallel with protein extracts from TKO HCC.
This strategy enabled the establishment of a standard curve that supports the
quantification of E2F1 and E2F3 expression in TKO HCC. To perform a gradient,
we loaded ultracentrifuge tubes with 5 ml of 20% Nycodenz and enabled the
establishment of a gradient by a 30-min ultracentrifugation at 100,000 g. A measure
of 100 mg of nuclear extract from TKO HCC cells were loaded on top of the
gradient and allowed to migrate through the gradient by another round of ultra-
centrifugation. Twenty fractions of 250 ml were collected and 40ml of each fraction
was loaded on a polyacrylamide gel.
For immunoblotting, unconjugated lysis samples were run on a 4–12%
polyacrylamide gel for 1.5 h at 150 V. Proteins were transferred to a nitrocellulose
membrane, blocked in 5% milk for 1 h then incubated at 4 C with primary
antibody overnight. Membrane was washed in TBST three times, and then probed
with an HRP-conjugated secondary antibody (anti-mouse, anti-rabbit, anti-goat)
for 1 h. Membrane was washed again three times in TBST. Amplified signal was
detected via ECL autoradiography. Antibody used: E2F1 (sc-193, 1/1,000), E2F2
(sc-833, 1/1,000), E2F3 (sc-893, 1/1,000), E2F4 (sc-1082, 1/500)), Actin (Cell
Signaling, 4970, 1/10,000), GAPDH (sc-25778, 1/5,000), Pontin (Sigma,
SAB4200194, 1/500), Reptin (Sigma, SAB1200115, 1/1,000), H2a.z (ab4174,
1/1,000), Glut4 (ab33780, 1/1,000), Gsk3b (Cell Signaling, 56765, 1/1,000).
Representative uncropped immunoblotting images are available in the
Supplementary Figs 7–9.
For immunohistochemistry, mouse HCC specimens were fixed in 10% buffered
formalin and embedded in paraffin. Standard deparaffinization, rehydration and
heat-induced epitope retrieval were performed. CD34 rabbit monoclonal antibody
(1:500, Abcam, cat.81289) was used as primary antibody, and the reactions were
visualized using the Vectastain ABC and DAB kit (Vector Laboratory). For hHCC
staining, tissue microarray were obtained from Biomax (HLiv-HCC060CD-01) and
processed as described above for antigen retrieval. Anti-E2F1 antibody (Abcam,
ab4070, 1/100) was used to detect E2F1 expression.
Gel shift assay. TKO HCC cells were harvested in 10 ml PBS at a density of
20 106 cells per ml. Cells were washed then resuspended in 200 ml of Cytoplasmic
Lysis Buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 2 mM MgCl2, 0.1 mM EDTA,
0.1% NP-40, Protease Inhibitor Cocktail) and incubated on ice for 5 min. Lysates
were spun down and pellet was washed twice in Wash Buffer (10 mM HEPES,
20 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, Protease Inhibitor Cocktail). The pellet
was then resuspended in twice its volume worth of Nuclear Extraction Buffer
(20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA, 0.63 mM NaCl, 25%
glycerol, Protease Inhibitor Cocktail) and incubated on ice for 30 min. Lysates were
spun down and supernatant collected as the nuclear extract. For DNA:protein
binding reactions, the following reagents were mixed and incubated at room
temperature for 20 min: NanoPure H2O, 7 ml Binding Buffer D (20 mM HEPES,
10 mM KCl, 0.2 mM EDTA, 10% glycerol, 5 mM dithiothreitol freshly added),
50 ng Poly dI:dC, 0.15% NP-40, 1 mg BSA, 5 mg nuclear extract and 20 fmol biotin-
labelled double-stranded DNA oligos. For the supershift assay, 5 mg of polyclonal
antibodies were added to the mix and pre-incubated for an additional 20 min
before adding the biotin-labelled double-stranded DNA oligos. Total reaction
volume was 20 ml for all samples. 5 ml of 5 Loading Buffer (Thermo 20148K)
were added to samples, which were then loaded and run on a pre-electrophoresed
4% polyacrylamide Tris Borate EDTA (TBE) gel at 4 C. Retarded samples were
transferred to a positively charged nylon membrane then visualized using a sta-
bilized streptavidin detection module (Thermo, 20148 Part No. 89880, 2–5 min
exposure).
DNAI hypersensitivity assay. Cell lines were crosslinked in 0.1% formaldehyde
for 10 min with rotation at room temperature and quenched with glycine for 5 min.
Cell pellet was resuspended in 1 ml cold 1 cell lysis buffer (60 mM KCl, 15 mM
NaCl, 5 mM MgCl2, 10 mM Tris, pH 7.4, 300 mM sucrose, 0.1 mM EGTA, 100
Halt protease and phosphatase inhibitor cocktail (#PI-78440), 0.1% IGEPAL) and
incubated on ice for 10 min. Nuclei were pelleted and resuspended in 50 ml nuclei
digestion buffer (60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 10 mM Tris, pH 7.4,
300 mM sucrose, 0.1 mM EGTA) per 1 million cell digestion. 5 ml of 100 mM CaCl2
was added to each digestion sample and equilibrated at room temperature for
10 min. Samples were incubated at 25 C for 5 min before DNase I was added and
reaction progressed for 10 min at 25 C. Digestion was terminated with the addi-
tion of 350ml of 0.1 mg ml 1 Proteinase K in Nuclear Lysis Buffer (300 mM
sodium acetate, 5 mM EDTA, 0.5% SDS). Samples were mixed by inversion and
placed in a 55 C water bath for 5 min and then 65 C water bath overnight to
reverse crosslinks. Additional Proteinase K was added to samples the next day for a
final concentration of 0.1 mg ml 1 and incubated at 55 C for 1 h. DNA was
isolated with phenol/chloroform/isoamyl (Invitrogen, Cat #15593-031) and
chloroform (Amaresco #0757) extractions before ethanol precipitation.
Computational analyses and statistics. All microarray data were processed and
analysed using the R/Bioconductor framework. Specifically, microarray data were
processed and normalized using the RMA algorithm and differential expression
analysis was performed using the ‘samr’ package. Heat map, boxplot and scatter
plot visualizations were produced using the ‘pheatmap’ package and ‘ggplot2’
package, respectively. 20–30,000 CT/TKO Sca1þ cells were harvested 2 weeks after
Tamoxifen treatment and array analysis were on MOE430 arrays (Affymetrix;
GSE63793). In Fig. 2a, we analysed publicly available data generated in CyclinB1-
GFP mouse model15 and determined the expression of a set of genes in hepatocytes
entering acute cell cycle activity upon partial hepatectomy. For Figs 2d and 7d,
P-value was estimated using a one-sided unpaired t-test. For Figs 2c, 3d and 7i,j,
P-value was estimated using a hypergeometric test. Experiments were repeated
until the collection of sufficient data for robust statistical analysis. *Po0.05;
**Po0.01; ***Po0.001. Error bars represent standard deviation.
Data availability. The mass spectrometry data have been deposited in the Dryad
database and are accessible at the following URL: http://dx.doi.org/10.5061/
dryad.31q7p.
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